glp 1 compound ending 🚨 FDA Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like semaglutide and tirzepatide, signaling a major shift in how these Compound versions of GLP-1 drugs

Restrain/Challenge Lack of Standardization and Clear Definition of GLP-1 Friendly Products The primary barrier to the growth of the GLP-1 friendly packaged food & beverage market is the lack of a defined concept of what constitutes "GLP-1 friendly." The phrase lacks a universal definition and has a lot of marketing behind it

That will prevent most compounding pharmacies from making and selling cheaper versions of the drug within the next few months

Contact your healthcare provider if you experience: Absent periods (amenorrhea): Missing three or more consecutive menstrual cycles if previously regular, or six or more months if previously irregular Heavy bleeding (menorrhagia): Soaking through a pad or tampon every hour for several consecutive hours, or periods lasting longer than seven days Severe pain: New or worsening menstrual cramping not relieved by over-the-counter medications Intermenstrual bleeding: Bleeding or spotting between periods that persists beyond initial treatment months Pregnancy possibility: Any missed period when pregnancy is possible, as tirzepatide is not recommended during pregnancy Urgent warning signs: Heavy bleeding with dizziness, fainting, rapid heartbeat, or severe weakness requires emergency evaluation Your healthcare provider may recommend specific investigations to evaluate persistent menstrual irregularities

In Phase II trials: Efinopegdutide (Merck/Johnson & Johnson/Hanmi Harma), VK2735 (Viking Therapeutics), BGM0504 (BrightGene), Pemvidutide (Altimmune/Spitfire Pharma), AMG133 (Amgen), Dapiglutide (Zealand Pharma), etc